Key statistics
On Monday, Immix Biopharma Inc (IMMX:NAQ) closed at 8.36, -6.80% below its 52-week high of 8.97, set on Feb 25, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 8.00 |
|---|---|
| High | 8.51 |
| Low | 7.95 |
| Bid | 7.62 |
| Offer | 8.35 |
| Previous close | 8.07 |
| Average volume | 618.40k |
|---|---|
| Shares outstanding | 52.15m |
| Free float | 40.49m |
| P/E (TTM) | -- |
| Market cap | 420.88m USD |
| EPS (TTM) | -0.7742 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 21:00 GMT.
More ▼
- Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
- Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
- Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
- At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
- Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
- Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
- Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
- Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
- Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference
- Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2
More ▼
